Mark Cuban Cost Plus Drug Company has solidified its latest collaboration by teaming up with Expion Health to address the surging costs associated with specialty drugs.
Under this partnership, Cost Plus Drugs' pricing model will seamlessly integrate into Expion's advanced pricing technology, combining the strengths of both entities to tackle the complexities of specialty medications. According to the announcement, this collaboration empowers payers with a sophisticated tool to navigate the modern landscape of specialty drug pricing.
Recognising the pressing need for innovation in the specialty pharmacy sector, the partners emphasised that these drugs, while constituting a small portion of prescriptions, contribute to over half of drug spending. Chris Westbrook, Chief Client Officer at Expion Health, highlighted the importance of addressing escalating specialty drug prices in today's environment. He stated, "Our relationship with Cost Plus Drugs embodies our commitment to providing efficient, cost-effective solutions. Together, we're reshaping the narrative around drug costs, setting a new industry standard."
The partners share a vision for a comprehensive overhaul of the specialty pharmacy landscape, expressing optimism about effecting positive change. Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug Company, underscored the shared commitment to delivering lower prescription drug prices to consumers, stating, “Cost Plus Drugs and Expion Health share a common goal of providing consumers the lowest possible price for their prescription medication. With Cost Plus Drugs, consumers can be confident they are getting a fair price and the convenience of medication mailed directly to their homes."
Click here to read the original news story.